WHO ICTRP trial
A Study to Assess Adverse Events and Disease Activity with Cedirogant (ABBV-157)…
JPRN-jRCT2061210069 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCT2061210069 |
|---|---|
| Public title | A Study to Assess Adverse Events and Disease Activity with Cedirogant (ABBV-157) in Adult Participants with Moderate to Severe Psoriasis |
| Scientific title | A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of Cedirogant (ABBV-157) in Adult Subjects with Moderate to Severe Psoriasis |
| Primary sponsor | Yamazaki Hayato |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Countries | United States;Japan;Canada;Japan |
| Conditions | Psoriasis |
| Interventions | The subject will receive cedirogant or placebo. |
| Registration date | Jan 14, 2022 |
| Target size | 200 |
| Secondary IDs | NCT05044234 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: